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Background
HIV-seropositive women have a higher risk of oncogenic
HPV infection, cervical neoplasia, and cervical cancer
than HIV-seronegative women. As HIV-seropositive
women begin to live longer due to effective highly active
antiretroviral therapy (HAART), their risk of developing
cervical cancer may increase. Little data exist regarding
the progression of cervical neoplasia in HIV seropositive
women from sub-Saharan Africa.
Methods
A longitudinal observational study of 2,106 HIV-seropo-
sitive women was performed to determine progression
rates of cytological outcomes in a government HIV
clinic in Johannesburg, South Africa, stratified by use of
HAART. The 2001 Bethesda grading system was to clas-
sify conventional Pap smear diagnoses. The effect of
HAART use at initial visit on rate of progression of cer-
vical neoplasia was determined using multivariate Pois-
son regression to obtain incidence rate ratios (IRRs)
adjusted for age, CD4 count, history of STDs, use of
hormonal contraception, parity, number of lifetime sex
partners, and age at first sexual contact.
Results
The cohort comprised 741 HIV-seropositive women with
at least two visits more than 6 months apart. Mean
followup time among these women was 565 days (median
449 days; intraquartile range 382-698 days). Among
women with a normal baseline Pap (n=326), 76 (23%)
progressed to LSIL or HSIL, at a rate of 16.0 (95% CL
12.8, 20.0) per 100 woman-years. Among women with
LSIL at baseline Pap (n=275), 46 (17%) progressed to
HSIL at a rate of 10.8 (95% CL 8.1, 14.4) per 100 woman-
years. Of the remaining 140 women with HSIL at base-
line Pap who not assessed treatment before repeat Pap
smear, none progressed to cancer. In multivariate Pois-
son regression, women receiving HAART at baseline visit
were less likely to progress than women not receiving
HAART at baseline (IRR=0.60, 95% CL 0.41, 0.87).
Results were similar regardless of baseline Pap result, and
using multivariate Cox proportional hazards models
(hazard ratio, 0.55, 95% CL 0.38, 0.80). In addition, lower
CD4 counts were associated with higher rates of cervical
neoplasic progression, although results were imprecise.
Conclusion
This is one of the first reports of progression rates of
cervical neoplasia among HIV-positive women. These
rates among women from South Africa are concerning.
There is an urgent need for broad-reaching screening/
treatment in Africa.
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